Abvance Therapeutics Secures Strategic Seed Financing & Leadership Expansion at ADA Scientific SessionsCHICAGO, June 24, 2025 (GLOBE NEWSWIRE) -- Abvance Therapeutics, a biotechnology company developing next-generation glucagon analogs and therapies to prevent hypoglycemia and improve glucose management, today announced the closing of its initial seed financing led by Zubi Capital, in conjunction with the 85th Scientific Sessions of the American Diabetes Association, held in Chicago. The financing will support the company’s early development programs and expansion of its executive and board leadership.
Abvance Therapeutics Announces Presentation of Human Clinical Data at the 85th Scientific Sessions of the American Diabetes AssociationCHICAGO, June 21, 2025 (GLOBE NEWSWIRE) -- Abvance Therapeutics, a biotechnology company developing next generation glucagon analogs and therapies to prevent hypoglycemia and improve glucose management, today announced the presentation of new human clinical data at the 85th Scientific Sessions of the American Diabetes Association (ADA), held in Chicago.
